Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Pharmaceutical Design

Volume 17 Issue 24
ISSN: 1381-6128
eISSN: 1873-4286

 

   All Titles

  Perinatal Gene Transfer to the Liver
  pp.2528-2541 (14) Authors: Tristan R. McKay, Ahad A. Rahim, Suzanne M.K. Buckley, Natalie J. Ward, Jerry K.Y.Chan, Steven J. Howe, Simon N. Waddington
 
 
      Abstract

The liver acts as a host to many functions hence raising the possibility that any one may be compromised by a single gene defect. Inherited or de novo mutations in these genes may result in relatively mild diseases or be so devastating that death within the first weeks or months of life is inevitable. Some diseases can be managed using conventional medicines whereas others are, as yet, untreatable. In this review we consider the application of early intervention gene therapy in neonatal and fetal preclinical studies. We appraise the tools of this technology, including lentivirus, adenovirus and adeno-associated virus (AAV)-based vectors. We highlight the application of these for a range of diseases including hemophilia, urea cycle disorders such as ornithine transcarbamylase deficiency, organic acidemias, lysosomal storage diseases including mucopolysaccharidoses, glycogen storage diseases and bile metabolism. We conclude by assessing the advantages and disadvantages associated with fetal and neonatal liver gene transfer.

 
  Keywords: Fetal gene therapy, in utero gene therapy, neonatal gene therapy, lysosomal storage disease, mucopolysaccharidosis, hemophilia, glycogen storage disease, liver, viral vector, Coagulation factor X
  Affiliation: Institute for Women's Health Gene Transfer Technology Group University College London 86-96 Chenies Mews London WC1E 6HX, UK.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers